2025 U.S. Most Favored Nation Policy: Implications and Strategic Guidance for Pharma and Biotech
The U.S. pharmaceutical landscape is set for another major shift. On May 12th, President Trump
The U.S. pharmaceutical landscape is set for another major shift. On May 12th, President Trump
France’s Reimbursed Early Access Programs (EAP) provide opportunities for reimbursement of new and innovative drugs
January 12th marked the launch of Joint Clinical Assessment (JCA), a key milestone in the
What is NTAP The New Technology Add-On Payment (NTAP) is a reimbursement program under the
In the competitive and resource-constrained world of biotechnology, achieving market access and reimbursement is critical.
The implementation of the Joint Clinical Assessment (JCA) in the European Union represents a notable
Justin Stindt Consultants is a fast growing consulting company offering strategy & market access consulting services to leading pharmaceutical, biotech and medical device clients. We operate in Europe and the United States.
